
Articles
-
1 week ago |
cnet.com | Suchandrima Bhowmik
Why You Can Trust CNET Our advice is expert-vetted and based on independent research, analysis and hands-on testing from our team of Certified Sleep Coaches. If you buy through our links, we may get a commission. Reviews ethics statement Wellness Sleep Forget melatonin. Here's why magnesium supplements are another top choice for quality sleep. Suchandrima Bhowmik Contributor Suchandrima Bhowmik is a freelance journalist who specializes in medical, health and nutrition writing.
-
1 week ago |
cnet.com | Suchandrima Bhowmik
Why You Can Trust CNET Our wellness advice is expert-vetted. Our top picks are based on our editors’ independent research, analysis, and hands-on testing. If you buy through our links, we may get a commission. Reviews ethics statement Wellness Learn about common flowers and plants that may be beautiful but pose a threat to you, your child or even your pet.
-
1 week ago |
yahoo.com | Suchandrima Bhowmik
With spring in full swing and warmer temperatures setting in, you may see more flowers and plants bloom in your backyard. Although they add beauty to your backyard, are you aware of whether the plants in your backyard are safe? Some of these beautiful flowers may pose a risk to you, your child and your pet. In this article, we explore some common toxic plants and flowers that often go unnoticed in your backyard.
-
2 weeks ago |
cnet.com | Suchandrima Bhowmik
When asked about sleep supplements, melatonin probably comes to mind first. It's undoubtedly the most popular. However, melatonin doesn't work for everyone. For some, it gives them bizarre dreams or leaves them feeling groggy the next day. If that sounds familiar, you're not out of luck when it comes to your sleep. Another sleep aid that's gained recent popularity is magnesium, which is said to calm your nervous system and help you get quality sleep.
-
2 weeks ago |
medcentral.com | Patrice Wendling |Suchandrima Bhowmik |Youssef Rddad
Extended treatment with a lower dose of apixaban (Eliquis) is noninferior to the full dose at preventing recurrent venous thromboembolism (VTE) with less bleeding in patients with active cancer who have completed at least 6 months of anticoagulation therapy, results from the API-CAT trial show. Findings were presented at the American College of Cardiology Annual Scientific Session and simultaneously published in the New England Journal of Medicine.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →